Remdesivir-Induced Liver Injury in a Patient With Coronavirus Disease 2019 and History of Congestive Hepatopathy.
| Autor: | Dividis GP; Department of Internal Medicine, Agios Pavlos General Hospital of Thessaloniki, Thessaloniki, GRC., Papadopoulos GE; Department of Cardiology, University Hospital of Ioannina, Ioannina, GRC., Karageorgiou I; Department of Internal Medicine, Agios Pavlos General Hospital of Thessaloniki, Thessaloniki, GRC., Kotronis G; Department of Internal Medicine, Agios Pavlos General Hospital of Thessaloniki, Thessaloniki, GRC. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Dec 09; Vol. 14 (12), pp. e32353. Date of Electronic Publication: 2022 Dec 09 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.32353 |
| Abstrakt: | Remdesivir is an antiviral agent used as supportive care in adults with SARS-COV2-induced pneumonia. We report a case of an 81-year-old patient who developed hepatocellular acute liver injury 48 hours after initiating remdesivir. During the investigation, other causes of hepatotoxicity were excluded. A decrease in transaminases and international normalized ratio (INR) was observed 24 hours after cessation of remdesivir. An abdominal CT demonstrated hepatic congestion, retrograde hepatic venous opacification shortly after intravenous contrast injection, and dilatation of hepatic veins and inferior vena cava. We suggest congestive hepatopathy secondary to remdesivir as a possible component of liver injury. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Dividis et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|